The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease.

ABSTRACT:

Background & aims

Patients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD) face a multifaceted disease burden which includes impaired health-related quality of life (HRQL) and potential stigmatization. We aimed to assess the burden of liver disease in patients with NAFLD and the relationship between experience of stigma and HRQL.

Methods

Members of the Global NASH Council created a survey about disease burden in NAFLD. Participants completed a 35-item questionnaire to assess liver disease burden (LDB) (seven domains), the 36-item CLDQ-NASH (six domains) survey to assess HRQL and reported their experience with stigmatization and discrimination.

Results

A total of 2,117 patients with NAFLD from 24 countries

SUBMITTER: Younossi ZM 

PROVIDER: S-EPMC11252535 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature